Skip Navigation



Rheumatology Advance Access published online on November 15, 2005

Rheumatology, doi:10.1093/rheumatology/kei182
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
45/4/392    most recent
kei182v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Koarada, S.
Right arrow Articles by Nagasawa, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koarada, S.
Right arrow Articles by Nagasawa, K.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Received July 14, 2005
Accepted September 30, 2005

Original Papers

Ex vivo CD4+ T-cell cytokine expression from patients with Sjögren's syndrome following in vitro stimulation to induce proliferation

S. Koarada 1 *, Y. Haruta 1, M. Mitamura 1, F. Morito 1, Y. Tada 1, A. Ohta 1, and K. Nagasawa 1

1 Division of Rheumatology, Saga Medical School, 5-1-1 Nabeshima, Saga, 849-8501 Japan

* To whom correspondence should be addressed.
S. Koarada, E-mail: koarada{at}med.saga-u.ac.jp


   Abstract

Objective. To assess ex vivo CD4+ T-cell cytokine expression from patients with primary Sjögren's syndrome (SS) following in vitro stimulation to induce proliferation, as proliferation is closely related to differentiation of cytokine-producing cells.

Methods. Peripheral blood mononuclear cells (PBMCs) separated from primary SS patients (n = 28) and controls (n = 25) were analysed. PBMCs were stimulated with concanavalin A followed by phorbol 12-myristate 13-acetate and ionomycin. Intracellular interferon-{gamma} (IFN-{gamma}) and interleukin-4 (IL)-4 in proliferating CD4+ T cells were assessed by flow cytometry. The proportion of cytokine-producing cells and proliferating cells in each division cycle was assessed using [5(and 6)-carboxyfluorescein diacetate, succinimidyl ester]-labelled CD4± T cells.

Results. The proportion of IFN-{gamma}+ proliferating CD4+ T cells in each cell division cycle from extraglandular SS was increased in glandular SS patients compared glandular SS patients with controls (P<0.05~0.01). The percentage of IFN-{gamma} single positive proliferating CD4+ T cells was greater in extraglandular SS patients (26.7±14.1%) compared with glandular SS (9.9 ± 9.1%) (P<0.01) and controls (9.4 ± 5.8%) (P<0.001). There was no significant difference in the percentages of IL-4+ proliferating CD4+ T cells among the groups. However, the proliferating response of CD4+ T cells was significantly decreased in extraglandular SS patients (percentage of proliferating cells 38.4 ± 18.6%) compared with that in glandular SS patients (64.2 ± 17.2%) (P<0.05) and controls (63.1±10.6%) (P<0.01).

Conclusions. CD4+ T cells from extraglandular SS patients may have a predisposition for entry into the IFN-{gamma}-producing effector pathway as a result of the stimulations. These results are helpful for understanding the immunological difference between glandular and extraglandular SS and the mechanisms of disease progression.

Keywords: Proliferation; CD4+ T cells; IFN-{gamma}; Sjögren's syndrome.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.